Huntington’s Disease

HD results in a complex interaction of motor speech and cognitive linguistic impairments. Redenlab possess a unique understanding of communication and swallowing changes that occur across the lifespan of the disease.

Phase 0

Publications

Realize the benefits of objective monitoring in Huntington’s disease

Objective, sensitive and reliable markers of change in communication add value to clinical trials in Huntington’s disease. The dominant inheritance of Huntington’s disease means there is an opportunity for therapies to act before symptoms manifest. For trials to be effective in this space we need markers of disease that are sensitive to disease in the premanifest stage. Redenlab scientists have developed field leading methods and data for detecting subtle changes in performance during the premanifest stage of Huntingon’s disease, highlighting the sensitivity of speech to pathology in premanifest Huntington’s disease. Digital measures of speech and language offer great promise for trialists motivated by using cutting edge tools linked to meaningful outcomes.

Enhance clinical outcome decisions for HD

Easy transition to objective assessment

Redenlab offers custom protocols and assessment strategies alongside Redenlab’s data capture and analysis tools that are easy to use and understand by patients, clincians and regulators alike.

Tap into motor u0026 cognitive outcomes

The competing demands of cognitive and motor decline in Huntington’s disease necessitate the inclusion of outcomes that capture both domains. Redenlab protocols draw on models of cognitive load, linguistic deficits and motor speech function to get the most out of brief and repeatable clinical protocol.

Reduce bias and variability

Conventional speech assessments are often subjective and susceptible to poor inter-rater reliability. Redenlab has built an analytics pipeline that provides objective markers of communication to ensure the fidelity of outcomes for monitoring change.

Monitor Huntington’s disease early and efficiently

Huntington’s disease usually manifests in middle age, but carriers of the Huntington gene mutation can present with subtle deficits years before diagnosis. Redenlab’s data capture tools have proven sensitive to symptom change in the prodromal stages of Huntington’s disease, making it a promising tool for early disease monitoring. Read more about our work in the links below or contact us to learn more.